Skip to main content
Contact Us
Subscribe
E-Edition
66°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2024
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Mirum Pharmaceuticals Inc
(NQ:
MIRM
)
23.57
-0.28 (-1.17%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 18, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Mirum Pharmaceuticals Inc
< Previous
1
2
3
Next >
Analyst Ratings For Mirum Pharmaceuticals
April 17, 2024
Via
Benzinga
$5M Bet On Snowflake? Check Out These 4 Stocks Insiders Are Buying
March 28, 2024
Although U.S. stocks closed higher on Wednesday, there were a few notable insider trades.
Via
Benzinga
Cracking The Code: Understanding Analyst Reviews For Mirum Pharmaceuticals
March 18, 2024
Via
Benzinga
FDA Approves Mirum's Livmarli For Liver Disease In Kids As Young As 5 Years: Analyst Bullish On Label Expansion Strategy
March 14, 2024
FDA approves Livmarli by Mirum Pharmaceuticals for cholestatic pruritus in PFIC patients ≥5 years old. Data from Phase 3 MARCH study. Analysts bullish on broader coverage in 2024, with price target...
Via
Benzinga
Exposures
Product Safety
Critical Insights From Mirum Pharmaceuticals Analyst Ratings: What You Need To Know
February 29, 2024
Via
Benzinga
Mirum Pharmaceuticals: Q4 Earnings Insights
February 28, 2024
Via
Benzinga
Preview: Mirum Pharmaceuticals's Earnings
February 27, 2024
Via
Benzinga
Where Mirum Pharmaceuticals Stands With Analysts
January 11, 2024
Via
Benzinga
The Latest Analyst Ratings For Mirum Pharmaceuticals
December 19, 2023
Via
Benzinga
11 Analysts Have This to Say About Mirum Pharmaceuticals
November 20, 2023
Via
Benzinga
Veradigm, Aehr Test Systems, Saratoga Investment And Other Big Stocks Moving Lower On Wednesday
January 10, 2024
U.S. stocks traded slightly higher, with the Dow Jones index gaining over 20 points on Wednesday. Shares of Veradigm Inc. (NASDAQ: MDRX) shares fell sharply during Wednesday’s session.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Uber To Rally Over 13%? Here Are 10 Top Analyst Forecasts For Tuesday
December 19, 2023
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
Via
Benzinga
Analyst Ratings for Mirum Pharmaceuticals
November 03, 2023
Via
Benzinga
Earnings Outlook For Mirum Pharmaceuticals
November 01, 2023
Via
Benzinga
7 Small-Cap Stocks That Get the Nod from Wall Street
October 11, 2023
Although small-cap stocks tend to be extremely risky, these compelling ideas just happen to get the nod from Wall Street analysts.
Via
InvestorPlace
Analyst Ratings for Mirum Pharmaceuticals
October 09, 2023
Via
Benzinga
Analyst Ratings for Mirum Pharmaceuticals
September 13, 2023
Via
Benzinga
Where Mirum Pharmaceuticals Stands With Analysts
August 21, 2023
Via
Benzinga
Why Lantheus Holdings Shares Are Trading Lower By Over 22%? Here Are Other Stocks Moving In Monday's Mid-Day Session
December 18, 2023
Shares of Lantheus Holdings, Inc. (NASDAQ: LNTH) fell sharply during Monday’s session after the company and POINT Biopharma announced topline results from the pivotal phase 3 SPLASH study in metastatic...
Via
Benzinga
Why Shares of Travere Therapeutics Are Slumping Thursday
September 21, 2023
A mixed trial could hurt a kidney drug's chances of full approval.
Via
The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For September 20, 2023
September 20, 2023
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 24, 2023
October 24, 2023
Via
Benzinga
Around $4M Bet On This Healthcare Stock? Check Out These 3 Stocks Insiders Are Buying
September 06, 2023
Although U.S. stocks closed mostly lower on Tuesday, there were a few notable insider trades.
Via
Benzinga
Raymond James Maintains Strong Buy Rating for Mirum Pharmaceuticals: Here's What You Need To Know
July 18, 2023
Via
Benzinga
The Latest Analyst Ratings for Mirum Pharmaceuticals
June 15, 2023
Via
Benzinga
Analyst Expectations for Mirum Pharmaceuticals's Future
May 22, 2023
Via
Benzinga
Mirum Pharmaceuticals: Q1 Earnings Insights
May 04, 2023
Via
Benzinga
Microsoft To Rally Around 16%? Here Are 10 Other Analyst Forecasts For Tuesday
July 18, 2023
B of A Securities boosted the price target for Camtek Ltd. (NASDAQ: CAMT) from $30 to $50. B of A Securities analyst Vivek Arya upgraded the stock from Neutral to Buy. Camtek shares rose 1.8% to $44.02...
Via
Benzinga
Travere Therapeutics Offloads Bile Acid Product Portfolio: Says Divestment Strengthens Financial Foundation
July 17, 2023
Travere Therapeutics Inc (NASDAQ: TVTX) has agreed to sell its bile acid product portfolio that, which includes Cholbam (cholic acid) and Chenodal (chenodiol), two medications, to Mirum Pharmaceuticals...
Via
Benzinga
Week In Review: Betta Pharma Enters $392 Million Deal For C4 Therapeutics’ NSCLC Drug
June 03, 2023
Hangzhou Betta Pharma acquired greater China rights for a novel non-small cell lung cancer drug from Boston’s C4 Therapeutics in a deal worth up to $392 million. Additionally, Lynk Pharma of Hangzhou...
Via
Talk Markets
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.